The ISABELA-1 and ISABELA-2 phase 3 trials evaluated ziritaxestat, an autotaxin inhibitor, in idiopathic pulmonary fibrosis, thus demonstrating the feasibility of large-scale testing of pathway-specific agents. This evidence concerns the gene ENPP2 and pulmonary fibrosis.